The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma

Inclusion Criteria:

1. Adult male or female aged ≥ 18;
2. Primary hepatocellular carcinoma confirmed by pathology;
3. There is no extrahepatic metastasis and portal vein tumor thrombus (Barcelona stage b), which cannot be removed after the evaluation of the surgeon, but there is a potential surgical opportunity after the tumor is significantly reduced;
4. Have not received treatment in the past;
5. At least 1 measurable lesion meeting the RECIST v1.1 or mRECIST standard;
6. Liver function is Child-Pugh A;
7. ECOG PS 0\~1 before entering the group;
8. Organs and bone marrow are fully functional:

9 Expected survival period ≥ 3 months; 10. Women of childbearing age who have not undergone surgical sterilization should take effective contraceptive measures within 3 months from enrollment to the end of the trial; 11. Sign a written informed consent and be able to comply with the visit and relevant procedures specified in the plan.

Exclusion Criteria:

1. The patient has any history of active autoimmune disease or autoimmune disease;
2. The patient is using immunosuppressant or systemic hormone therapy to suppress immune function;
3. Known central nervous system metastasis or hepatic encephalopathy;
4. Severe allergic reaction to other monoclonal antibodies;
5. Have a history of organ transplantation;
6. The patient has the serious basic disease and cannot tolerate treatment;
7. The patient has previously received other anti-PD-1 antibody treatment or other anti-PD-1/PD-L1 immunotherapy, or has previously received apatinib treatment;